Functional outcome | ||||||
---|---|---|---|---|---|---|
Favourable (n = 55) | Unfavourable (n = 37) | Univariate | Multivariate | |||
p value | p value | OR | CI 95% | |||
Age (> 65y) | 22 (40%) | 22 (59%) | 0.067 | 0.06 | 2.59 | [0.96–7.02] |
Female | 18 (33%) | 12 (32%) | 0.97 | – | ||
APACHE II | 20 [15–24] | 26 [21–33] | 0.02 | – | ||
non–neuro APACHE II | 17 [10–23] | 19 [14–25] | 0.31 | – | ||
APACHE II (> 23) | 20 (36%) | 21 (57%) | 0.054 | 0.5 | 1.39 | [053–3.66] |
CAM-ICU + | 18/47 (38%) | 11/23 (49%) | 0.45 | – | ||
CRS-R | 22 [11–23] | 3 [1–18] | < 0.001 | – | ||
GCS | 14 [11–15] | 7 [3–14] | < 0.001 | – | ||
Sedation | 12 (22%) | 18 (49%) | 0.007 | – | ||
Propofol dose (mg/kg/day) | 17 [3–47] | 25 [15–35] | 0.25 | – | ||
Propofol duration (day) | 1 [1–2] | 3 [2–4.5] | 0.007 | – | ||
Mdz dose (mg/kg/day) | 0.6 [0.6–1.5] | 0.2 [0.1–04] | 0.07 | – | ||
Mdz duration (day) | 2 [2–3.5] | 1.5 [1–1.5] | 0.27 | – | ||
Dxd dose (µg/kg/day) | 7.1 [na] | 7.9 [6–16.7] | 1 | – | ||
Dxd duration (day) | 2 [na] | 2 [1–3] | 1 | – | ||
Vasoactive drugs | 46 (84%) | 30 (81%) | 0.75 | – | ||
Mechanical ventilation | 34 (62%) | 30 (81%) | 0.049 | – | ||
SAE | 35 (64%) | 31 (84%) | 0.035 | 0.21 | 2.8 | [0.66–6.52] |
cEEG rhythmic and periodic patterns | ||||||
RDA | 25 (45%) | 23 (62%) | 0.11 | – | ||
PDs | 8 (15%) | 15 (41%) | 0.005 | 0.02 | 3.82 | [1.27–11.49] |
PDs burden | [0–46%] | [0–60%] | 0.008 | – | ||
cEEG background | ||||||
Reactivity | 48 (87%) | 26 (70%) | 0.044 | – | ||
Sleep | 36 (65%) | 19 (51%) | 0.17 | – | ||
PDR | 52 (95%) | 30 (81%) | 0.042 | – | ||
High grade mSynek scale | 11 (20%) | 22 (60%) | < 0.001 | – | ||
SB/suppressed | 0 (0%) | 3 (8%) | 0.06 | – | ||
Discontinuous/Low voltage | 4 (7%) | 7 (19%) | 0.09 | – |